![Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | Endocrine Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | Endocrine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12020-020-02475-2/MediaObjects/12020_2020_2475_Fig1_HTML.png)
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | Endocrine
![Amazon.co.jp: B Clarinet Musical Instrument, Silver Plated, Ebony Wood, Ebony Woodwind, For Children, Adults, Beginner, Trial Instrument : Musical Instruments Amazon.co.jp: B Clarinet Musical Instrument, Silver Plated, Ebony Wood, Ebony Woodwind, For Children, Adults, Beginner, Trial Instrument : Musical Instruments](https://m.media-amazon.com/images/I/61jDsrVd9tL._AC_UF894,1000_QL80_.jpg)
Amazon.co.jp: B Clarinet Musical Instrument, Silver Plated, Ebony Wood, Ebony Woodwind, For Children, Adults, Beginner, Trial Instrument : Musical Instruments
![Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency - Ronny Allan - Living with Neuroendocrine Cancer Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency - Ronny Allan - Living with Neuroendocrine Cancer](https://i0.wp.com/ronnyallan.net/wp-content/uploads/2020/09/clarinet-forte-1.jpg?fit=4000%2C2250&ssl=1)
Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency - Ronny Allan - Living with Neuroendocrine Cancer
![Duilio Rocha Filho on X: "2⃣ CLARINET FORTE - lanreotide 120 mg q14 days in GEP-NET pts w/ progression on LAN 🤔PanNET: mPFS 5.6 mo 🤔Midgut: mPFS 8.3 mo 🚫Inferior results if Duilio Rocha Filho on X: "2⃣ CLARINET FORTE - lanreotide 120 mg q14 days in GEP-NET pts w/ progression on LAN 🤔PanNET: mPFS 5.6 mo 🤔Midgut: mPFS 8.3 mo 🚫Inferior results if](https://pbs.twimg.com/media/EiXGHP8XgAIoyC_.png)
Duilio Rocha Filho on X: "2⃣ CLARINET FORTE - lanreotide 120 mg q14 days in GEP-NET pts w/ progression on LAN 🤔PanNET: mPFS 5.6 mo 🤔Midgut: mPFS 8.3 mo 🚫Inferior results if
Manejo de TNE GI y pulmonares G1-G2. Miguel Navarro. Oncología Médica. Hospital Universitario de Salamanca. Reunión ACLO.
![PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram](https://www.researchgate.net/publication/346230520/figure/fig2/AS:962699366236162@1606536823208/PFS-for-lanreotide-autogel-depot-from-the-CLARINET-core-study-and-the-OLE-and-PFS-for_Q320.jpg)
PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram
![Essential Concepts in the Use of Somatostatin Analogues in Patients with Neuroendocrine Tumors (Transcript) Essential Concepts in the Use of Somatostatin Analogues in Patients with Neuroendocrine Tumors (Transcript)](https://img.medscapestatic.com/article/839/490/Slide26.png)
Essential Concepts in the Use of Somatostatin Analogues in Patients with Neuroendocrine Tumors (Transcript)
![Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors | Journal of Gastrointestinal Cancer Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors | Journal of Gastrointestinal Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12029-016-9866-9/MediaObjects/12029_2016_9866_Fig3_HTML.gif)